Cellectis reports Phase 1 data for leukemia therapy lasme-cel

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/6/2026

1. ZS
2. LULU
3. IOT
4. SPY
5. PATH
6. DOCU
7. ASAN
8. NVDA
9. GWRE
10. CIEN

Go back to Cellectis reports Phase 1 data for leukemia therapy lasme-cel
(NASDAQ: CLLS) Delayed: 3.24 -0.08 (2.41%)
Previous Close $3.32    52 Week High $37.55 
Open $3.41    52 Week Low $16.35 
Day High $3.41    P/E N/A 
Day Low $3.21    EPS $0.00 
Volume 4,835